You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 140 No. 2, February 1986 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (21)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Hypercalciuria Associated With Long-term Administration of Calcitriol (1,25-Dihydroxyvitamin D3)

Action of Hydrochlorothiazide

Fernando Santos, MD; M. J. Vernon Smith, MD, PhD; James C. M. Chan, MD

Am J Dis Child. 1986;140(2):139-142.


Abstract



• Urine calcium excretion was evaluated in 19 patients before and after calcitriol (1,25-dihydroxyvitamin D3) treatment that was followed up for a five- to seven-year period. The effects of increases of calcitriol dosage and modifications of calciuria with hydrochlorothiazide were systematically examined. The urine calcium excretion before calcitriol therapy was 2.3±0.8 mg/kg/day (mean-± SEM) and the urine calcium-creatinine concentration ratio was 0.12±0.04. With the dose of calcitriol at 23 ng/kg/day, these values increased to 3.2±0.8 mg/kg/day and 0.19±0.04, respectively. Following double dose of calcitriol (44 ng/kg/day), increments in calciuria and urinary calcium/creatinine concentration of 1.4±0.6 mg/kg/day and 0.10±0.03, respectively, were observed. With concomitant administration of hydrochlorothiazide (1 to 2 mg/kg/day) therapy at maintenance dose and calcitriol (31 ng/kg/day), the urine calcium excretion effectively decreased by 1.3±0.6 mg/kg/day and the urine calcium-creatinine concentration ratio by 0.05 ± 0.02. The results suggest that children with calcium-phosphate disorders who require long-term treatment with calcitriol must be carefully monitored in terms of urine calcium excretion, especially when the dosages are increased to achieve maximal therapeutic efficacy. Calciuria induced by calcitriol administration is effectively reversed by addition of hydrochlorothiazide to the treatment regimen.

(AJDC 1986;140:139-142)



Author Affiliations



From the Children's Medical Center (Drs Santos, Smith, and Chan) and the Departments of Surgery (Dr Smith) and Pediatrics (Drs Santos and Chan), Medical College of Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond. After sabbatical leave during which he did this work, Dr Santos is now back at Children's Hospital Instituto Nacional de la Salud and the University of Oviedo, Asturias, Spain.


Footnotes



Accepted for publication Oct 3, 1985.

Reprint requests to Medical College of Virginia Station, Box 498, Richmond, VA 23298 (Dr Chan).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Synthetic Human Parathyroid Hormone 1-34 Replacement Therapy: A Randomized Crossover Trial Comparing Pump Versus Injections in the Treatment of Chronic Hypoparathyroidism
Winer et al.
J. Clin. Endocrinol. Metab. 2012;97:391-399.
ABSTRACT | FULL TEXT  

Long-Term Treatment of 12 Children with Chronic Hypoparathyroidism: A Randomized Trial Comparing Synthetic Human Parathyroid Hormone 1-34 versus Calcitriol and Calcium
Winer et al.
J. Clin. Endocrinol. Metab. 2010;95:2680-2688.
ABSTRACT | FULL TEXT  

Percutaneous Parathyroid Ethanol Ablation in Patients with Multiple Endocrine Neoplasia Type 1
Veldman et al.
Am. J. Roentgenol. 2008;191:1740-1744.
ABSTRACT | FULL TEXT  

Effects of Once Versus Twice-Daily Parathyroid Hormone 1-34 Therapy in Children with Hypoparathyroidism
Winer et al.
J. Clin. Endocrinol. Metab. 2008;93:3389-3395.
ABSTRACT | FULL TEXT  

Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients
Riechelmann et al.
JNCI J Natl Cancer Inst 2007;99:592-600.
ABSTRACT | FULL TEXT  

Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1-34) Versus Calcitriol and Calcium
Winer et al.
J. Clin. Endocrinol. Metab. 2003;88:4214-4220.
ABSTRACT | FULL TEXT  

Hydrochlorothiazide Effectively Reduces Urinary Calcium Excretion in Two Japanese Patients with Gain-of-Function Mutations of the Calcium-Sensing Receptor Gene
Sato et al.
J. Clin. Endocrinol. Metab. 2002;87:3068-3073.
ABSTRACT | FULL TEXT  

Thiazide Diuretics Arrest the Progression of Nephrocalcinosis in Children With X-Linked Hypophosphatemia
Seikaly and Baum
Pediatrics 2001;108:e6-e6.
ABSTRACT | FULL TEXT  

A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1-34 in Treatment of Hypoparathyroidism
Winer et al.
J. Clin. Endocrinol. Metab. 1998;83:3480-3486.
ABSTRACT | FULL TEXT  

Familial Hypoparathyroidism: Identification of a Novel Gain of Function Mutation in Transmembrane Domain 5 of the Calcium-Sensing Receptor
Watanabe et al.
J. Clin. Endocrinol. Metab. 1998;83:2497-2502.
ABSTRACT | FULL TEXT  

Sporadic Hypoparathyroidism Caused by de Novo Gain- of-Function Mutations of the Ca2+-Sensing Receptor
De Luca et al.
J. Clin. Endocrinol. Metab. 1997;82:2710-2715.
ABSTRACT | FULL TEXT  

Synthetic Human Parathyroid Hormone 1-34 vs Calcitriol and Calcium in the Treatment of Hypoparathyroidism: Results of a Short-term Randomized Crossover Trial
Winer et al.
JAMA 1996;276:631-636.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.